FDAnews
www.fdanews.com/articles/81775-abmaxis-achieves-milestone-in-collaboration-with-merck

ABMAXIS ACHIEVES MILESTONE IN COLLABORATION WITH MERCK

October 19, 2005

Abmaxis, Inc., a privately held biopharmaceutical company, today announced that it has achieved a major milestone under its collaboration agreement with Merck & Co., Inc. Under the terms of the agreement, Abmaxis was to optimize an undisclosed Merck human monoclonal antibody for potential therapeutic use. The Abmaxis team has successfully re-engineered Merck's human monoclonal antibody and improved antibody affinity more than 70-fold while retaining its specificity, triggering a milestone payment from Merck.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-18-2005/0004171411&EDATE=)